Maria Ladea este conferențiar universitar la Catedra de psihiatrie a UMF „Carol Davila” București și coordonatoarea cărții „Nutriția și sănătatea mintală” (2012). Este medic primar psihiatru și șefă de secție la Spitalul Clinic de Psihiatrie „Prof. dr. Alexandru Obregia” București
Andra Morășan este medic rezident psihiatru la Spitalul Clinic de Psihiatrie „Prof. dr. Alexandru Obregia” București
Asocierea diabet–depresie
Corelații etiopatogenice
Particularitățile asocierii neuropatiei diabetice cu depresia
Atitudinea terapeutică
Concluzii
Bibliografie
1. WHO. Depression. Fact sheet 369. Geneva, 2015 Oct
2. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry. 1997 Mar;170:205-28
3. Chesney E et al. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014 Jun;13(2):153-60
4. Narayan KM et al. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003 Oct 8;290(14):1884-90
5. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442
6. Said G. Diabetic neuropathy--a review. Nat Clin Pract Neurol. 2007 Jun;3(6):331-40
7. David AS et al. Lishman’s Organic Psychiatry. A Textbook of Neuropsychiatry. 4th edition. Wiley-Blackwell, 2009
8. Harrison NA, Kopelman MD. Endocrine diseases and metabolic disorders. In: David AS et al. (editors), Lishman’s Organic Psychiatry. A Textbook of Neuropsychiatry. 4th edition. Wiley-Blackwell, 2009
9. Geringer ES et al. Depression and diabetic neuropathy: a complex relationship. J Geriatr Psychiatry Neurol. 1988 Jan;1(1):11-5
10. Anderson RJ et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001 Jun;24(6):1069-78
11. Ali S et al. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006 Nov;23(11):1165-73.
12. Moussavi S et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007 Sep 8;370(9590):851-8
13. Golden SH et al. Examining a bidirectional association between depressive symptoms and diabetes. JAMA. 2008 Jun 18;299(23):2751-9
14. de Groot M et al. Association of depression and diabetes complications: a meta-analysis. Psychosom Med. 2001 Jul-Aug;63(4):619-30
15. Lustman PJ et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care. 2000 Jul;23(7):934-42
16. Lustman PJ et al. Recent advances in understanding depression in adults with diabetes. Curr Diab Rep. 2007 Apr;7(2):114-22
17. Simon GE et al. Diabetes complications and depression as predictors of health service costs. Gen Hosp Psychiatry. 2005 Sep-Oct;27(5):344-51
18. Kivimäki M et al. Common mental disorder and obesity: insight from four repeat measures over 19 years: prospective Whitehall II cohort study. BMJ. 2009 Oct 6;339:b3765
19. Rush AJ et al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry. 1996 Oct;57(10):470-84
20. Vreeburg SA et al. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch Gen Psychiatry. 2009 Jun;66(6):617-26
21. Fountoulakis KN et al. Revisiting the Dexamethasone Suppression Test in unipolar major depression: an exploratory study. Ann Gen Psychiatry. 2008 Nov 13;7:22
22. Otte C et al. Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: The Heart and Soul Study. Biol Psychiatry. 2004 Aug 15;56(4):241-7
23. Harris TO et al. Morning cortisol as a risk factor for subsequent major depressive disorder in adult women. Br J Psychiatry. 2000 Dec;177:505-10
24. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry. 2001 Mar 1;49(5):391-404
25. Kunugi H et al. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a Multicenter Study. Neuropsychopharmacology. 2006 Jan;31(1):212-20
26. Surwit RS et al. Stress and diabetes mellitus. Diabetes Care. 1992 Oct;15(10):1413-22
27. Wing RR et al. Psychologic stress and blood glucose levels in nondiabetic subjects. Psychosom Med. 1985 Nov-Dec;47(6):558-64
28. Musselman DL et al. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry. 2003 Aug 1;54(3):317-29
29. Vinik AI et al. Diabetic autonomic neuropathy. Diabetes Care. 2003 May;26(5):1553-79
30. Kemp AH et al. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biol Psychiatry. 2010 Jun 1;67(11):1067-74
31. Smith RS. The macrophage theory of depression. Med Hypotheses. 1991 Aug;35(4):298-306
32. Howren MB et al. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009 Feb;71(2):171-86
33. Davidson KW et al. Relation of inflammation to depression and incident coronary heart disease (from the Canadian Nova Scotia Health Survey [NSHS95] Prospective Population Study). Am J Cardiol. 2009 Mar 15;103(6):755-61
34. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004 Mar;27(3):813-23
35. Bastard JP et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006 Mar;17(1):4-12
36. Pradhan AD et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001 Jul 18;286(3):327-34
37. Cesari M et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003 Nov 11;108(19):2317-22
38. Li S et al. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009 Jul 8;302(2):179-88
39. Larsen CM et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007 Apr 12;356(15):1517-26
40. Larsen CM et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care. 2009 Sep;32(9):1663-8
41. Paile-Hyvärinen M et al. Depression and its association with diabetes, cardiovascular disease, and birth weight. Ann Med. 2007;39(8):634-40
42. Barker DJ. Fetal origins of coronary heart disease. BMJ. 1995 Jul 15;311(6998):171-4
43. Hudson JI et al. Binge-eating disorder as a distinct familial phenotype in obese individuals. Arch Gen Psychiatry. 2006 Mar;63(3):313-9
44. Yanovski SZ et al. Association of binge eating disorder and psychiatric comorbidity in obese subjects. Am J Psychiatry. 1993 Oct;150(10):1472-9
45. Krabbe KS et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia. 2007 Feb;50(2):431-8
46. Wang J et al. Is BDNF biological link between depression and type 2 diabetes mellitus? Med Hypotheses. 2012 Aug;79(2):255-8
47. Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med. 2004;5(1):11-25
48. Brunoni AR et al. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol. 2008 Dec;11(8):1169-80
49. Frodl T et al. Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J Psychiatry Neurosci. 2008 Sep;33(5):423-30
50. Piccinni A et al. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J Affect Disord. 2008 Jan;105(1-3):279-83
51. Ladea M, Bran M. Brain derived neurotrophic factor (BDNF) levels in depressed women treated with open-label escitalopram. Psychiatr Danub. 2013 Jun;25(2):128-32
52. Ladea M et al. Brain derived neurotrophic factor levels and hippocampal volume in depressed patients treated with escitalopram. Farmacia. 2014;62(1)
53. Talbot F, Nouwen A. A review of the relationship between depression and diabetes in adults: is there a link? Diabetes Care. 2000 Oct;23(10):1556-62
54. Pouwer F et al. Rates and risks for co-morbid depression in patients with Type 2 diabetes mellitus: results from a community-based study. Diabetologia. 2003 Jul;46(7):892-8
55. Lustman PJ et al. The course of major depression in diabetes. Gen Hosp Psychiatry. 1997 Mar;19(2):138-43
56. Vileikyte L et al. Diabetic peripheral neuropathy and depressive symptoms: the association revisited. Diabetes Care. 2005 Oct;28(10):2378-83
57. Takahashi Y, Hirata Y. A follow-up study of painful diabetic neuropathy: physical and psychological aspects. Tohoku J Exp Med. 1983 Dec;141(4):463-71
58. Alleman CJ et al. Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: A review of the literature. Diabetes Res Clin Pract. 2015 Aug;109(2):215-25
59. Vinik AI. Diagnosis and management of diabetic neuropathy. Clin Geriatr Med. 1999 May;15(2):293-320
60. Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry. 2001 Mar;13(1):31-41
61. Walters JM et al. The effect of norepinephrine on insulin secretion and glucose effectiveness in non-insulin-dependent diabetes. Metabolism. 1997 Dec;46(12):1448-53
62. Zilliox L, Russell JW. Maintaining efficacy in the treatment of diabetic peripheral neuropathic pain: role of duloxetine. Diabetes Metab Syndr Obes. 2010 Jan 6;3:7-17
63. Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med. 1998 Jan 26;158(2):134-40
64. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabetes Care. 2008 Feb;31 Suppl 2:S255-61
65. Turkington RW. Depression masquerading as diabetic neuropathy. JAMA. 1980 Mar 21;243(11):1147-50
66. Max MB et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992
May 7;326(19):1250-6
67. Yasuda H et al. Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52-week, open-label study. J Diabetes Investig. 2016 Jan;7(1):100-8
68. Backonja M et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998 Dec 2;280(21):1831-6
69. Tassone DM et al. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007 Jan;29(1):26-48
70. Bandelow B et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry. 2002 Oct;3(4):171-99
71. Vinik A et al. Prediction of pregabalin-mediated pain response by severity of sleep disturbance in patients with painful diabetic neuropathy and post-herpetic neuralgia. Pain Med. 2014 Apr;15(4):661-70
72. Darbà J et al. Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective. Adv Ther. 2014 Jan;31(1):1-29
73. Marchettini P et al. Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy? Eur J Pain. 2016 Mar;20(3):472-82
74. Bunner AE et al. A dietary intervention for chronic diabetic neuropathy pain: a randomized controlled pilot study. Nutr Diabetes. 2015 May 26;5:e158
75. Crane MG, Sample C. Regression of diabetic neuropathy with total vegetarian (vegan) diet. J Nutr Med 1994;4:431-9
76. Markowitz SM et al. A review of treating depression in diabetes: emerging findings. Psychosomatics. 2011 Jan-Feb;52(1):1-18
77. Bogner HR et al. Integrated management of type 2 diabetes mellitus and depression treatment to improve medication adherence: a randomized controlled trial. Ann Fam Med. 2012 Jan-Feb;10(1):15-22
78. Tesfaye S et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10):2285-93
Dacă vrei să fii la curent cu tot ce se întâmplă în lumea medicală, abonează-te la „Viața Medicală”, publicația profesională, socială și culturală a profesioniștilor în Sănătate din România!
Titularii abonamentelor pe 12 luni sunt creditați astfel de:
Cookie-urile ne ajută să vă îmbunătățim experiența pe site-ul nostru. Prin continuarea navigării pe site-ul www.viata-medicala.ro, veți accepta implicit folosirea de cookie-uri pe parcursul vizitei dumneavoastră.
Da, sunt de acord Aflați mai multe